| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697740 | Clinical Oncology | 2017 | 7 Pages |
Abstract
Despite the use of relatively low biological doses respecting spinal cord constraints, SABR results in excellent 2 year local control rates with low morbidity. Through careful selection of patients with oligometastases, most patients are alive and free from widespread metastases at 2 years. This cohort warrants further investigation in clinical trials of SABR.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J.H. Chang, S. Gandhidasan, R. Finnigan, D. Whalley, R. Nair, A. Herschtal, T. Eade, A. Kneebone, J. Ruben, M. Foote, S. Siva,